吉西他滨联合顺铂一线治疗转移性三阴性乳腺癌的临床观察(2)
 |
| 第1页 |
参见附件。
[2] Perou CM，Sorlie T，Eisen MB，et al. Molecular portraits of human breast tumors[J]. Nature，2000，406(6797)：747-752.
[3] Sotiriou C，Neo SY，McShane LM，et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study[J]. Proc Natl Acad Sci，2003，100：10393-10398.
[4] Eneman JD，Wood ME，Muss HB. Selecting adjuvant endocrine therapy for breast cancer[J]. Oncology，2004，18(14)：1733-1744.
[5] Michaud LB. Treatment-experienced breast cancer[J]. Am J Health Syst Pharm，2008，65(10 Suppl 3)：4-9.
[6] Seidman AD. Gemcitabine as single agent therapy in the management of advanced breast cancer[J]. Oncology，2001，15(Suppl 3)：11-14.
[7] Bhattacharyya A，Ear US，Koler BH，et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin[J]. J Biol Chem，2000，275(31)：23899.
[8] Van Moorsel CJ，Veeman G，Bergman AM，et al. Combination chemotherapy studies with gemcitabine[J]. Semin Oncol，1997，24(2 Suppl 7)：17-23.
[9] Achanta G，Pelicano H，Feng L，et al. Interaction of p53 and DNA-PK in response to nucleoside analogues：Potential role as a sensor complex for DNA damage[J]. Cancer Res，2001，61：8723-8729.
(收稿日期：2012-09-12 本文编辑：郭静娟)
您现在查看是摘要介绍页，详见PDF附件(1637kb)。